Categorization of COVID-19 severity to determine mortality risk

被引:9
|
作者
Garry, Elizabeth M. [1 ]
Weckstein, Andrew R. [1 ]
Quinto, Kenneth [2 ]
Bradley, Marie C. [3 ]
Lasky, Tamar [4 ]
Chakravarty, Aloka [4 ]
Leonard, Sandy [5 ]
Vititoe, Sarah E. [1 ]
Easthausen, Imaani J. [1 ]
Rassen, Jeremy A. [1 ]
Gatto, Nicolle M. [1 ]
机构
[1] Aetion Inc, New York, NY 10001 USA
[2] US FDA, Off Med Policy, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[3] US FDA, Div Epidemiol, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[4] US FDA, Off Commissioner, Silver Spring, MD USA
[5] HealthVerity, Partnerships & RWD, Philadelphia, PA USA
关键词
administrative claims; healthcare; COVID-19; severity of illness index;
D O I
10.1002/pds.5436
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose Algorithms for classification of inpatient COVID-19 severity are necessary for confounding control in studies using real-world data. Methods Using Healthverity chargemaster and claims data, we selected patients hospitalized with COVID-19 between April 2020 and February 2021, and classified them by severity at admission using an algorithm we developed based on respiratory support requirements (supplemental oxygen or non-invasive ventilation, O2/NIV, invasive mechanical ventilation, IMV, or NEITHER). To evaluate the utility of the algorithm, patients were followed from admission until death, discharge, or a 28-day maximum to report mortality risks and rates overall and by stratified by severity. Trends for heterogeneity in mortality risk and rate across severity classifications were evaluated using Cochran-Armitage and Logrank trend tests, respectively. Results Among 118 117 patients, the algorithm categorized patients in increasing severity as NEITHER (36.7%), O2/NIV (54.3%), and IMV (9.0%). Associated mortality risk (and 95% CI) was 11.8% (11.6-12.0%) overall and increased with severity [3.4% (3.2-3.5%), 11.5% (11.3-11.8%), 47.3% (46.3-48.2%); p < 0.001]. Mortality rate per 1000 person-days (and 95% CI) was 15.1 (14.9-15.4) overall and increased with severity [5.7 (5.4-6.0), 14.5 (14.2-14.9), 32.7 (31.8-33.6); p < 0.001]. Conclusion As expected, we observed a positive association between the algorithm-defined severity on admission and 28-day mortality risk and rate. Although performance remains to be validated, this provides some assurance that this algorithm may be used for confounding control or stratification in treatment effect studies.
引用
收藏
页码:721 / 728
页数:8
相关论文
共 50 条
  • [41] Valuing mortality risk in the time of COVID-19
    James K. Hammitt
    [J]. Journal of Risk and Uncertainty, 2020, 61 : 129 - 154
  • [42] Covid-19, hypercoagulability and risk of mortality in schizophrenia
    Garcia-Ribera, Carles
    Carrasco, Marina
    Ruiz-Ripoll, Ada
    [J]. ACTAS ESPANOLAS DE PSIQUIATRIA, 2021, 49 (04): : 194 - 195
  • [43] Risk Factors for COVID-19 Mortality in Malaysia
    Hanis, Tengku Muhammad
    Arifin, Wan Nor
    Musa, Kamarul Imran
    Hasani, Wan Shakira Rodzlan
    Nawi, Che Muhammad Nur Hidayat Che
    Shahrani, Shahnon Anuar
    Chen, Xin Wee
    Suliman, Mohd Azmi
    Khan, Erwan Ershad Ahmad
    Aziz, Wira Alfatah Ab
    Said, Mohamad Zarudin Mat
    [J]. MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2022, 29 (06): : 123 - 131
  • [44] Valuing mortality risk in the time of COVID-19
    Hammitt, James K.
    [J]. JOURNAL OF RISK AND UNCERTAINTY, 2020, 61 (02) : 129 - 154
  • [45] Cancer Patients and Risk of Mortality for COVID-19
    Curigliano, Giuseppe
    [J]. CANCER CELL, 2020, 38 (02) : 161 - 163
  • [46] HLA variability may help determine COVID-19 disease severity
    Dengler, V. L.
    [J]. GENETICS IN MEDICINE, 2020, 22 (07) : 1132 - 1132
  • [47] Mortality and severity among Covid-19 patients who already vaccinated with inactivated Covid-19 vaccine
    Tanod, D. V.
    Abdurrahmanto, A.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [48] COVID-19 Mortality and Severity in Cancer Patients and Cancer Survivors
    Park, Jae -Min
    Koo, Hye Yeon
    Lee, Jae-ryun
    Lee, Hyejin
    Lee, Jin Yong
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2024, 39 (02)
  • [49] Serum cholinesterase associated with COVID-19 pneumonia severity and mortality
    Nakajima, Kento
    Abe, Takeru
    Saji, Ryo
    Ogawa, Fumihiro
    Taniguchi, Hayato
    Yamaguchi, Keishi
    Sakai, Kazuya
    Nakagawa, Tomoki
    Matsumura, Reo
    Oi, Yasufumi
    Nishii, Mototsugu
    Takeuchi, Ichiro
    [J]. JOURNAL OF INFECTION, 2021, 82 (02) : 321 - 323
  • [50] Gender Differences in Patients With COVID-19: Focus on Severity and Mortality
    Jin, Jian-Min
    Bai, Peng
    He, Wei
    Wu, Fei
    Liu, Xiao-Fang
    Han, De-Min
    Liu, Shi
    Yang, Jin-Kui
    [J]. FRONTIERS IN PUBLIC HEALTH, 2020, 8